Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
21 evidence topics · 14 sources
Treatment goal of minimal manifestation status: international consensus guidance
“Goals for the treatment of MG. MGFA Task Force Post-Intervention Status (PIS) classification Minimal Manifestation Status (MMS) or better,3 with no more than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) medication side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal symptom expression as a patient-reported treatment goal
“‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MSE, as a patient‐centric endpoint, can be used alongside clinician‐assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steroid-sparing strategy and tapering
“Tapering of IS drugs is associated with risk of relapse, which may necessitate upward adjustments in dose. The risk of relapse is higher in patients who are symptomatic, or after rapid taper. d. It is usually necessary to maintain some immunosuppression for many years, sometimes for life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with generalized MG should be given a non‐steroid immunosuppressant to achieve a better clinical response and enable steroid dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tapering of corticosteroids, and non‐steroidal immunosuppressants, should be considered after 1–2 years in patients in stable remission or with minimal symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for adverse effects of immunosuppression
“Patients must be monitored for potential adverse effects and complications from IS drugs. Changing to an alternative IS agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients on steroids should be monitored for blood pressure, body weight, bone mineral density, blood glucose levels, sleep, and mood problems.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring disease activity with MG-ADL and QMG
“The QMG takes up to 25 min to complete and requires technician training, a hand‐held dynamometer, a spirometer, and a stopwatch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical practice or in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical training and shared goal setting: Nordic guidance
“Adapted physical training is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients and doctors should together define ambitious treatment goals” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for CRS, ICANS, and hematotoxicity after CAR T-cell therapy in autoimmune disease: EBMT recommendations
Hospitalization, distance to the treating center, and caregiver presence after CAR T-cell therapy: EBMT recommendations
“For hospitalization and distance to the accredited treating center, we refer to current EBMT guidelines for CT and ideally up to 14 days for AD patients without severe reactions. Patients should be located within 60 min of the center with the continuous presence of a caregiver educated to identify the potential complications maintained for a year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daily CRS and ICANS monitoring and myelotoxicity surveillance: CD19 CAR T-cell case series in MG
“Patients were monitored daily for the development of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS) during the first 10 days following anti-CD19 CAR T cell infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Myelotoxicity was defined as grade III or IV neutropenia or leukocytopenia persisting for more than 28 days and was monitored prospectively using regular laboratory assessments, performed several times per week during the first 30 days, approximately biweekly between days 30 and 90, and at longer intervals thereafter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term observation revealed an episode of pneumonia in patient MG3, associated with B cell aplasia and hypogammaglobulinemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neutropenia, infection, and hypogammaglobulinemia management after lymphodepletion and CAR T-cell infusion: phase 1 trial in refractory gMG
“For neutrophil deficiency (absolute neutrophil count less than 1.0 × 109/L), granulocyte colony-stimulating factor and prophylactic antibiotics (mostly sulfamethoxazole and cephalosporins) were given.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those with severe infections or hypogammaglobulinemia (IgG less than 4 g/L), 0.4–0.6 g/kg of intravenous immunoglobulin was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antimicrobial prophylaxis after CAR T-cell therapy: EBMT recommendations
“The risk of infection depends on the AD and degree of immunosuppression, and management should be carefully discussed upfront by a multidisciplinary team meeting (disease specialist, infection-disease specialist, hematologists and CART experts). A follow-up of potential infectious complications should be considered mandatory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sufficiently long anti-viral and antibacterial prophylaxis should be maintained according to patient individual risk and in line with institutional guidelines and current EBMT guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vaccination before and after CAR T-cell therapy: EBMT recommendations
“Vaccinations status should be assessed and updated before LD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vaccination after CART therapy is effective and risk consideration should guide the decision to vaccinate before the procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Live vaccines are contraindicated in AD patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vaccination before immunosuppressive therapy and before complement inhibitors: 2026 international consensus
“Clinicians should refer patients with MG to their primary care clinician or appropriate specialty (e.g., infectious disease) to complete immunization schedules, per local/national/World Health Organization guidelines and per local prescribing information for MG therapies as part of immunosuppressive therapy planning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should refer patients with gMG for whom complement inhibitor therapies may be a future consideration to their primary care clinician or appropriate specialist to complete meningococcal vaccination and other treatment-specific vaccination, per local/national/World Health Organization guidelines and per local drug prescribing information.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Leukapheresis: T-cell counts, venous access, and immunosuppressant washout: EBMT recommendations
“To achieve a good product, drug-specific washout periods before leukapheresis have to be considered to optimize T cell fitness as listed in Table 5. Usual recommendations for a successful CART production advice for 200/mcl CD3+ T cell counts, but CD3+ T cell counts >50/mcl can be sufficient. Secure venous access has to be guaranteed in ADs, when planning leukapheresis and lymphodepleting conditioning (LD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Washout of MG-relevant immunotherapies before leukapheresis: EBMT recommendations
| Therapy | Recommendation in autoimmune disease |
|---|---|
| Steroids | “May be administered at dosages ≤10 mg/day prednisone (or equivalent), by 7 days before leukapheresis and before LD;”View highlighted excerpt for this quote |
| Mycophenolate mofetil, azathioprine, calcineurin inhibitors, mTOR inhibitors, and JAK inhibitors | “Discontinued at least 2 weeks before leukapheresis”View highlighted excerpt for this quote |
| Cyclophosphamide and methotrexate | “Discontinued at least 3 weeks before leukapheresis”View highlighted excerpt for this quote |
| Belimumab and B cell targeting antibodies (e.g. anti CD20) | “Discontinued at least 1 week before leukapheresis”View highlighted excerpt for this quote |
Timing of immunosuppressants around apheresis and lymphodepletion, and pre-lymphodepletion assessment of pulmonary reserve and bulbar function in MG
“EULAR–EBMT guidance allows low‐dose prednisone up to 7.5 mg 1 day prior to apheresis but advises tapering cell‐cycle blockers 4 weeks before lymphodepletion so that transduced T‐cells expand without pharmacologic brakes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trial registries for autoimmune cellular therapies therefore recommend a meticulous pre‐diagnostic evaluation that captures comorbid infection, pulmonary reserve and bulbar function before lymphodepletion is even considered” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Application of the Immune Effector Cell‐Associated Encephalopathy (ICE) score beside continuous EEG was able to detect subclinical seizures in almost half of the patients whose formal ICANS grade had remained 0–1, suggesting that conventional grading alone is insufficient once neuromuscular weakness complicates the examination” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prolonged B-cell aplasia, hypogammaglobulinemia, and infections after CAR T-cell therapy
“A frequent long‐term consequence of anti‐CD19 CAR T‐cell therapy is prolonged B cell aplasia, persisting for years in up to 38% of patients and often resulting in hypogammaglobulinemia and increased infection risk requiring immunoglobulin replacement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Severe infections are frequent in the early period following CAR-T reinfusion, warranting antimicrobial prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypogammaglobulinaemia is typically prolonged and may necessitate treatment of supplemental Immunoglobulin Replacement Therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Frequency of CRS, ICANS, hypogammaglobulinemia, cytopenias, and infection after CAR-based therapy in autoimmune disease: meta-analysis of 56 studies
“Of 3367 records screened, 56 studies met the inclusion criteria (15 eligible for meta-analysis; 41 synthesized qualitatively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all AIDs, CRS of any grade occurred in 0·63, but grade ≥ 3 CRS and any grade of ICANS were negligible (both 0·00). Hypogammaglobulinaemia of any grade occurred in 0·47, while grade ≥ 3 events were rare. Cytopenias were common: neutropenia and anemia of any grade were most frequent. Severe cytopenias occurred in ≤0·3. Infection within 3 months occurred in 0·29.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regular assessment of symptom burden, treatment burden, and quality of life; shared decision making: 2026 international consensus
“Clinicians should regularly assess a patient with MG at all disease stages for symptom burden, treatment burden, and quality of life, using the same measures to build an ongoing, overall picture of the disease and its impact.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should engage patients with MG and their family/caregivers, as appropriate, to play an active role in shared decision making, so that patients' personal goals, values, and preferences are considered when discussing treatment plans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients receiving glucocorticoids, clinicians should aim to reduce the glucocorticoid dose to prednisone equivalent ≤10 mg/d and optimally to ≤5 mg/d, using alternative agents as necessary, and monitor patients closely for MG worsening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
IgG monitoring under FcRn inhibitors and rituximab: German-Austrian expert guidance
“Drug‐specific safety parameters must be assessed before initiation and at every switch of immunotherapy. These include monitoring of IgG levels under FcRn‐I and RTX therapy (especially when used in combination).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote